ALIMTA is not indicated for treatment of patients with squamous cell NSCLC. Myelosuppression is usually the dose-limiting toxicity with ALIMTA therapy.About Non-Small Cell Lung Cancer (NSCLC)Lung cancer has long been the most common cancer in the world, representing nearly 13 percent of all new cancers and causing nearly 1.4 million deaths annually. 2 About 85 percent of all lung cancers are NSCLC. 3 The liver, bones and brain are potential targets if the cancerous cells spread to other areas in the body.
ALIMTA® Extends Survival In Continuation Maintenance Setting For Specific Lung Cancer Patients
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts